DKK3 and prostate cancer: By targeting Dickkopf WNT signaling pathway inhibitor 3 (DKK3), miR-1303 is known to activate Wnt/β-catenin signaling and facilitate prostate cancer progression by regulating proliferation, migration, and invasion [92].